Jagsonpal Pharmaceuticals doubles Q1 profit to INR 108m

Jagsonpal Pharmaceuticals reported net profit of INR 107.95 million for the quarter ended June 30, 2025, more than double the INR 53.29 million recorded in the same period last year.

Revenue from operations rose to INR 756.12 million from INR 614.39 million year-on-year. Basic earnings per share increased to INR 1.60 from INR 0.78 in Q1 2024.

The board recommended a final dividend of INR 2.5 per equity share for the year ended March 31, 2025.